Capsule Summary Slidesets

Share

Program Content

Activities

  • BRCAAway Phase II Trial
    BRCAAway: Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in HRR-Mutant Metastatic CRPC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 30, 2024

  • CONTACT-02
    CONTACT-02: Cabozantinib + Atezolizumab vs Second Novel Hormonal Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 31, 2024

  • EV-302/KEYNOTE-A39
    Phase III EV-302/KEYNOTE-A39: Subgroup Analyses of EV + Pembrolizumab vs Chemotherapy in Previously Untreated Adv Urothelial Carcinoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 01, 2024

  • Erdafitinib and EV Sequencing in aUC
    Erdafitinib and Enfortumab Vedotin Sequencing in Patients With FGFR2/3-Altered aUC: UNITE Database Retrospective Analysis
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 01, 2024

  • PemCab in aUC
    PemCab: Phase II Study of First-line Cabozantinib + Pembrolizumab for Cisplatin- or Platinum-Ineligible Patients With aUC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 02, 2024

  • KEYNOTE-564
    KEYNOTE-564: Updated Analysis of a Phase III Trial of Adjuvant Pembrolizumab vs Placebo After Nephrectomy for Clear Cell Renal Cell Carcinoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 02, 2024

  • A031501 AMBASSADOR
    A031501 AMBASSADOR: Phase III Trial of Pembrolizumab vs Observation as Adjuvant Therapy for High-Risk Muscle-Invasive Urothelial Carcinoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 02, 2024

Provided by

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Exelixis, Inc., and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

AstraZeneca

Exelixis, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC